Calliditas Therapeutics
Manufacturing · Sweden · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Kungsbron 1, Stockholm, Stockholm, 111 2...Phone Number
+46 84113005Website
www.calliditas.seRevenue
$152.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Calliditas Therapeutics
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique two-step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US. The company is listed on Nasdaq Stockholm (ticker: CALTX).Explore more
Calliditas Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Calliditas Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Calliditas Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Calliditas Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Calliditas Therapeutics launches new products
Click to see if Calliditas Therapeutics had a recent Job posting/layoffs
Check out if Calliditas Therapeutics is spiking on competitors!
Check if Calliditas Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Calliditas Therapeutics recently announced quarterly report
Calliditas Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Calliditas Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Calliditas Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Calliditas Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Calliditas Therapeutics.
Calliditas Therapeutics financials insights
Gather financial insights about Calliditas Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$75M
Calliditas Therapeutics Tech Stack
A closer look at the technologies used by Calliditas Therapeutics
Most Recent Scoops
Open Position
Open Position
Executive Move
Person-Based
Executive Moves, Pharmaceuticals, Clinical Operations, Healthcare Operations
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Calliditas Therapeutics News & Media
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET. AboutCalliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Stockholm, Sweden, September 3, 2024 – Following the announcement by Asahi Kasei Corporation (“Asahi Kasei”) on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas” or the “Company”), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of CallidNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)
The shareholders of Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the extraordinary general meeting on Monday 30 September 2024 at 12:00 p.m. CEST at Advokatfirman Vinge’s premises on Smålandsgatan 20, SE-111 46, Stockholm, Sweden. Registration starts at 11:30 a.m. CEST. Background Asahi Kasei Corporation (“Asahi Kasei”), which has announced that the public offer made regarding the company’s shares has beCalliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript
Calliditas Therapeutics AB (publ) (NASDAQ:NASDAQ:CALT) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ETCompany ParticipantsRenée Aguiar-Lucander...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Calliditas Therapeutics
Sign Up For FreeTo access detailed company insights
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on t... Read More
